<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02451228</url>
  </required_header>
  <id_info>
    <org_study_id>15-0067</org_study_id>
    <secondary_id>1R01HD083003-01</secondary_id>
    <nct_id>NCT02451228</nct_id>
  </id_info>
  <brief_title>Indomethacin PK and PD Therapy in Pregnancy</brief_title>
  <official_title>Pharmacokinetic and Pharmacogenomic Approach to Indomethacin Therapy in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will follow pregnant women who are taking indomethacin as Standard of Care (SOC)&#xD;
      for the indications of preterm labor (PTL), short cervix, or other indications, to evaluate&#xD;
      the pharmacokinetics (PK), what the body does to the drug, and pharmacodynamics (PD),&#xD;
      effectiveness of the drug in treating the specific intended disease process of this&#xD;
      medication. This will help us develop more information for medication dosing specific to&#xD;
      pregnant women experiencing preterm labor.&#xD;
&#xD;
      Indomethacin is often prescribed to pregnant women presenting with preterm labor or shortened&#xD;
      cervix, which places them at risk for preterm labor and delivery. Indomethacin has been used&#xD;
      since the 1970s to prolong pregnancy by decreasing uterine contractions. However, despite the&#xD;
      widespread use of indomethacin in pregnancy, there is limited information available to help&#xD;
      physicians determine how much indomethacin to prescribe and how often to prescribe it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Opportunistic study of indomethacin prescribed to patients per standard of care. Determine&#xD;
      the pharmacokinetics, pharmacodynamics and pharmacogenomics of Indomethacin in pregnant&#xD;
      patients with the hypothesis that that estradiol levels during pregnancy (12-32 weeks of&#xD;
      gestation) and CYP2C9 polymorphisms affect the PK of indomethacin, and subsequently, the&#xD;
      response to indomethacin therapy in patients at risk of Preterm birth (PTB). This hypothesis&#xD;
      will be tested with the following specific aims: (1) Determine the PK of indomethacin in&#xD;
      pregnant women at risk of PTB and its PD effects on reducing the rate of PTB before 34 weeks&#xD;
      of gestation, as well as any associations between the PK and secondary maternal/neonatal&#xD;
      clinical outcomes; (2) Determine the effects of maternal levels of estradiol in mid-pregnancy&#xD;
      and CYP2C9 polymorphisms on indomethacin biotransformation to O-desmethylindomethacin in&#xD;
      pregnant patients; (3) Construct a population PK/PD model of indomethacin in patients at risk&#xD;
      of PTB (12-32 weeks of gestation) in order to optimize the dose and the dosing frequency for&#xD;
      indomethacin prescribed to each individual based on covariates such as race/ethnicity, CYP2C9&#xD;
      genotype, gestational age, estradiol levels, smoking status, and body mass index (BMI). The&#xD;
      investigators will enroll 300 subjects with spontaneous preterm labor (sPTL) or shortened&#xD;
      cervix in a prospective opportunistic PK study designed to correlate the PK of indomethacin,&#xD;
      patient genotype, and clinical outcomes. The investigators will merge dosing, sampling,&#xD;
      demographic, and clinical information with the drug concentration data and use population PK&#xD;
      methodologies to analyze the data using nonlinear mixed effect modeling. Quantification of&#xD;
      the differences within and between individuals allows for identification of covariates (e.g.,&#xD;
      CYP2C9 genotype, estradiol levels, BMI, etc.) that can explain variability and affect drug&#xD;
      exposure. These covariates, if significant, can then be used in the future to optimize dosing&#xD;
      in individual patients at risk for PTB. Achieving this goal of individualized indomethacin&#xD;
      therapy could have a significant impact on clinical practice and improve maternal and&#xD;
      neonatal outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>Enrollment until delivery of the participant</time_frame>
    <description>Gestational age at delivery calculated from the first day of last menstrual period unless &quot;unsure&quot; and then it will be calculated from ultrasound measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal outcomes</measure>
    <time_frame>Enrollment until delivery and maternal discharge</time_frame>
    <description>Diagnosed maternal outcomes including oligohydramnios, chorioamnionitis, preterm premature rupture of membranes, venous thromboembolism, pulmonary edema, postpartum hemorrhage, and maternal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcomes</measure>
    <time_frame>The earlier of neonatal discharge or up to 120 days postnatal</time_frame>
    <description>Diagnosed neonatal outcomes including birth weight, APGAR scores, neonatal sepsis, respiratory distress syndrome, patent ductus arteriosis, necrotizing enterocolitis, broncopulmonary dysplasia, paraventricular leukomalacia, intraventricular hemorrhage, fetal, or neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal admission to Neonatal intensive care unit (NICU)</measure>
    <time_frame>The earlier of neonatal discharge or up to 120 days postnatal</time_frame>
    <description>Documentation of NICU admission [yes/no]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the Neonatal intensive care unit (NICU)</measure>
    <time_frame>The earlier of neonatal discharge or up to 120 days postnatal</time_frame>
    <description>If admitted to the NICU, number of days in the NICU</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Premature Labor</condition>
  <condition>Pregnancy</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Single-group</arm_group_label>
    <description>Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serial blood collection</intervention_name>
    <description>Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.</description>
    <arm_group_label>Single-group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal Venous Blood for serum Maternal Blood for DNA (for CYP2C9) Maternal Urine Cord Blood&#xD;
      (Umbilical Vein and Artery) for serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multi-center study including 300 pregnant women between 12-32 weeks of gestation&#xD;
        at risk of PTB (sPTL or shortened cervix with or without funneling membranes) or other&#xD;
        conditions to whom indomethacin is prescribed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be enrolled in the study, patients must meet all of the following criteria:&#xD;
&#xD;
          1. Age at least 18 years&#xD;
&#xD;
          2. Singleton gestation&#xD;
&#xD;
          3. 12 0/7 to 32 0/7 weeks gestation (see Gestational Age Determination section 3.2.1.1)&#xD;
&#xD;
          4. Patient receiving indomethacin for any of the following diagnoses:&#xD;
&#xD;
               1. Preterm labor: regular uterine contractions with documented cervical change or&#xD;
                  dilatation â‰¥ 2 cm and 80% effacement&#xD;
&#xD;
               2. Cervical shortening (&lt; 2.5 cm documented on transvaginal ultrasound) with or&#xD;
                  without funneling membranes&#xD;
&#xD;
               3. Planned cervical cerclage or emergent cerclage&#xD;
&#xD;
               4. Other condition whereby Indomethacin is indicated&#xD;
&#xD;
          5. Maternal and fetal condition allows anticipated delay of delivery for more than 24&#xD;
             hours -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria include:&#xD;
&#xD;
               1. Contraindications to indomethacin use (history of maternal bleeding disorder,&#xD;
                  thrombocytopenia, maternal hepatic, gastrointestinal ulcerative, or renal&#xD;
                  dysfunction, asthma)&#xD;
&#xD;
               2. Known fetal abnormality, genetic syndrome, or intrauterine fetal demise&#xD;
&#xD;
               3. Anticipated delivery in less than 24 hours, cervical dilatation &gt; 6 cm&#xD;
&#xD;
               4. Preterm premature rupture of membranes&#xD;
&#xD;
               5. Suspected chorioamnionitis&#xD;
&#xD;
               6. Oligohydramnios (DVP &lt; 2 cm)&#xD;
&#xD;
               7. Congenital Uterine anomaly&#xD;
&#xD;
               8. Vaginal bleeding due to suspected placental abruption or placenta previa&#xD;
&#xD;
               9. Planned preterm delivery for maternal/fetal indications&#xD;
&#xD;
              10. Non-reassuring fetal status&#xD;
&#xD;
              11. Planned delivery outside UTMB or participation in another intervention trial&#xD;
                  which may affect maternal or neonatal outcomes&#xD;
&#xD;
              12. Unsure gestational age due to possibility of intrauterine growth restriction&#xD;
&#xD;
              13. Hematocrit &lt;28% (as determined by most recent result within 1 month of&#xD;
                  enrollment)&#xD;
&#xD;
              14. Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Hankins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Rytting, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch, Dept of OB/GYN</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>June 9, 2019</last_update_submitted>
  <last_update_submitted_qc>June 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Preterm labor</keyword>
  <keyword>Preterm birth</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Short Cervix</keyword>
  <keyword>CYP2C9 Genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Once published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

